Prodrugs of 4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1,2,2-trimethylpiperazine and 4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d3)piperazine
The development of 4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1,2,2-trimethylpiperazine prodrugs addresses the challenges of CNS disease treatments by enhancing uptake and reducing adverse events, offering improved therapeutic efficacy for conditions like schizophrenia.
Patent Information
- Application Number
- JP2021529329
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2018-12-03
- Filing Date
- 2019-11-27
- Publication Date
- 2024-11-14
- Estimated Expiration
- 2039-11-27
AI Technical Summary
Existing treatments for central nervous system (CNS) diseases, particularly schizophrenia, face challenges with adverse events and inadequate control of dopamine D1 and D2 receptor activity, necessitating improved pharmacokinetic profiles and reduced adverse effects.
Development of 4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1,2,2-trimethylpiperazine and its deuterated variant, which act as prodrugs, designed to enhance uptake and delay release, thereby reducing adverse events and improving therapeutic efficacy.
The prodrugs provide enhanced pharmacokinetic profiles, delaying release and reducing adverse events, making them effective for treating CNS diseases like schizophrenia with improved therapeutic outcomes.
Smart Images

Figure 0007583719000001 
Figure 0007583719000002 
Figure 0007583719000003
Abstract
Description
[Technical field]
[0001] The present invention relates to prodrugs of 4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1,2,2-trimethylpiperazine in the forms 1a and 1b; and 4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d3)piperazine in the forms 2a and 2b. [ka] (In the formula, X - is a counter ion) or a pharma- ceutically acceptable salt thereof.
[0002] The present invention also provides pharmaceutical compositions comprising a prodrug of the present invention or a pharma- ceutically acceptable salt thereof. [Background technology]
[0003] A group of trans isomers of 3-aryl-1-(1-piperazinyl)indanes substituted at the 2- and / or 3-positions of the piperazine ring has been described in WO 93 / 22293 and Klaus P. Bogeso, Drug Hunting, the Medicinal Chemistry of 1-Piperazino-3-phenylindans and Related Compounds, 1998, ISBN 87-88085-10-4 (see, for example, compound 69 in Table 3 on page 47 and Table 9A on page 101). The compounds are described as having high affinity for dopamine D1 and D2 receptors and 5-HT2 receptors, and have been suggested to be useful in the treatment of several disorders of the central nervous system, including schizophrenia.
[0004] Trans-racemic 4-((6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine can be synthesized by methods similar to those outlined in, for example, Bogeso et al., J.Med.Chem., 1995, 38, p. 4380-4392 and WO 93 / 22293. The preparation of this compound by resolution of trans-racemic 4-((6-chloro-3-phenyl-indan-1-yl)-1,2,2-trimethyl-piperazine is described by Bogeso et al. in J.Med.Chem., 1995, 38, p. 4380-4392, see Table 5, compound (-)-38. The process described involves the use of (+)-ditoluoyltartaric acid for resolution in ethyl acetate, and the compound is isolated as the fumarate salt.
[0005] 4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1,2,2-trimethylpiperazine was subsequently given the International Nonproprietary Name (INN) Diclonapine by the WHO. Salts of 4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1,2,2-trimethylpiperazine were disclosed in WO 2005 / 016900, but later patent applications disclose alternative methods for the preparation of 4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1,2,2-trimethylpiperazine (WO 2011 / 003423) and resolution of the same compound (WO 2012 / 093165).
[0006] 4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d3)piperazine is a compound that is deuterium-ionized at the positions shown in 2a and 2b. 2H) enriched 4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1,2,2-trimethylpiperazine. 4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d3)piperazine is disclosed in WO 2012 / 176066, which also discloses a synthetic route for obtaining 4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d3)piperazine.
[0007] WO 2014 / 096151 discloses a further synthetic route for the conversion of 3,5-dichloro-1-(phenyl-d5)-indane to give 4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d3)piperazine.
[0008] The present invention provides prodrugs of 4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1,2,2-trimethylpiperazine and 4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d3)piperazine. The prodrugs of the present invention improve the uptake of, for example, 4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1,2,2-trimethylpiperazine and 4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d3)piperazine, and 4-(( The release of 1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1,2,2-trimethylpiperazine and 4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d3)piperazine may be delayed or the level of potential adverse events may be reduced. Summary of the Invention
[0009] The present invention relates to compounds that are prodrugs as shown below (1a and 1b; 2a and 2b): [ka] and pharma- ceutically acceptable salts thereof.
[0010] 1a and 2a have the R configuration at the chiral nitrogen atom, and 1b and 2b have the S configuration at the chiral nitrogen atom.
[0011] In one embodiment, the invention provides a prodrug as defined above, or a pharma- ceutically acceptable salt thereof, for use in therapy.
[0012] In one embodiment, the present invention provides a pharmaceutical composition comprising a prodrug of the present invention as defined above or a pharma- ceutically acceptable salt thereof and one or more pharma- ceutically acceptable excipients.
[0013] In one embodiment, the invention provides a prodrug as defined above, or a pharma- ceutically acceptable salt thereof, for use in a method of treatment of a CNS disorder.
[0014] In one embodiment, the present invention provides the use of a prodrug, or a pharma- ceutically acceptable salt thereof, as defined above for use in the manufacture of a medicament for the treatment of a CNS disorder.
[0015] In one embodiment, the present invention provides a method for the treatment of a CNS disease comprising the administration of a therapeutically effective amount of a prodrug as defined above or a pharma- ceutically acceptable salt thereof to a patient in need thereof. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0016] Detailed Description of the Invention The present invention provides compounds that are prodrugs as shown below (1a and 1b; 2a and 2b): [ka] 1a and 2a have the R configuration at the chiral nitrogen atom, and 1b and 2b have the S configuration at the chiral nitrogen atom.
[0017] R is a straight or branched C1-C such as methyl. 11 Alkyl; or C3-C such as cyclohexylmethyl or cyclohexylethyl 10 It is cycloalkyl.
[0018] The -CHOC(O)R attached to 4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1,2,2-trimethylpiperazine or 4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d3)piperazine is referred to as a prodrug group.
[0019] X - is a halide anion such as chloride, bromide, or iodide, an optionally fluorinated C1-C aryl anion such as mesylate, tosylate, trifluoromethanesulfonate, or nonafluorobutanesulfonate; 10 Optionally fluorinated linear or branched C1-C aryl groups such as sulfonates and trifluoroacetates. 11 carboxylates.
[0020] Compounds 1a and 1b have a natural hydrogen isotope distribution, while 2a and 2b contain deuterium ( 2 H) is enriched.
[0021] Prodrug A typical prodrug is a compound that may not have any pharmacological activity by itself, but is metabolized to provide a pharmacologically active compound when administered to a patient. More specifically, the prodrugs of the present invention are compounds that are metabolized to provide 4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1,2,2-trimethylpiperazine (prodrugs 1a and 1b) or 4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d3)piperazine (prodrugs 2a and 2b) when administered to a patient.
[0022] salt Some of the prodrugs of the present invention may be provided as pharmaceutically acceptable acid addition salts. The term pharmaceutically acceptable salts includes salts formed with inorganic and / or organic acids, such as hydrochloride acid, hydrobromide acid, phosphoric acid, nitrous acid, sulfuric acid, benzoic acid, citric acid, gluconic acid, lactic acid, maleic acid, succinic acid, tartaric acid, acetic acid, propionic acid, oxalic acid, maleic acid, fumaric acid, glutamic acid, pyroglutamic acid, salicylic acid, salicylic acid, saccharin, and sulfonic acids, such as methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, and benzenesulfonic acid. Some of the acids listed above are diacids or triacids, i.e., acids containing two or three acid hydrogens, such as phosphoric acid, sulfuric acid, fumaric acid, and maleic acid. Diacids and triacids may form 1:1, 1:2, or 1:3 (triacid) salts, ie, salts formed between two or three molecules of a compound of the invention and one molecule of an acid.
[0023] Additional examples of acids and bases useful for forming pharma- ceutically acceptable salts can be found, for example, in Stahl and Wermuth (Eds) “Handbook of Pharmaceutical salts. Properties, selection, and use”, Wiley-VCH, 2008.
[0024] Therapeutically effective amount In the present context, the term "therapeutically effective amount" of a compound means an amount sufficient to cure, alleviate or partially arrest the clinical symptoms of a given disease and its complications in a therapeutic intervention involving the administration of said compound. Amounts sufficient to achieve this are defined as "therapeutically effective amounts". The effective amount for each purpose will depend on the severity of the disease or wound as well as the weight and general condition of the subject. The prodrugs of the present invention are typically administered in the form of 1 to 30 mg of 4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1,2,2-trimethylpiperazine or 4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-( and 4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1,2,2-trimethylpiperazine or 4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d3)piperazine, are administered to achieve a therapeutic effect comparable to administration of 1 to 60 mg of 4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1,2,2-trimethylpiperazine or 4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d3)piperazine. This means that, for example, "20 mg of 4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1,2,2-trimethylpiperazine or 4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d3)piperazine" must be adjusted for the weight of the prodrug group, however the actual amount administered. This means 20 mg of 4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1,2,2-trimethylpiperazine or 4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d3)piperazine free base which must be further adjusted for the weight of the counter ion.
[0025] In the present context, "treatment" or "treating" is intended to indicate the management and care of the patient with the purpose of palliating, arresting, partially arresting or slowing the progression of clinical signs of the disease or curing the disease. The patient to be treated is preferably a mammal, in particular a human being.
[0026] disease In the present context, "CNS disease" refers to a disease in the central nervous system. For example, as disclosed in WO 2005 / 016900 and WO 2012 / 176066, 4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1,2,2-trimethylpiperazine and 4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d3)piperazine (i.e., 1a, 1b, 2a , and the parent form of 2b), it is expected that the compounds will also be useful in the treatment of psychosis, in particular schizophrenia or other disorders that contain psychotic symptoms, such as, for example, schizophrenia, treatment-resistant schizophrenia (TRS) schizophreniform disorder, schizoaffective disorder, delusional disorder, brief psychotic disorder, shared psychotic disorder, as well as other psychotic disorders or disorders that present with psychotic symptoms, for example, bipolar disorder, such as mania in bipolar disorder, and other CNS disorders, including, but not limited to, schizophrenia. The compounds and / or compositions of the present invention can further be used to treat disorders such as those described in, for example, U.S. Pat. Nos. 5,807,855; 7,648,991; 7,767,683; 7,772,240; 8,076,342; U.S. Patent Application Publication No. 2008 / 0269248; U.S. Patent Application Publication No. 2010 / 0069676; U.S. Patent Application Publication No. 2011 / 0178094; U.S. Patent Application Publication No. 2011 / 0207744; WO 2005 / 016900; EP 0638073; and J. Med. Chem. 1995, 38, 4380-4392, each of which is incorporated herein by reference in its entirety.This specification also relates to the medical use of the compounds of the invention as combination therapy in combination with other therapeutic agents such as those described in, for example, U.S. Pat. Nos. 5,807,855; 7,648,991; 7,767,683; 7,772,240; 8,076,342; U.S. Patent Application Publication No. 2008 / 0269248; U.S. Patent Application Publication No. 2010 / 0069676; U.S. Patent Application Publication No. 2011 / 0178094; U.S. Patent Application Publication No. 2011 / 0207744; WO 2005 / 016900; EP 0638073; and J. Med. Chem. 1995, 38, 4380-4392, each of which is incorporated herein in its entirety.
[0027] In the present context, treatment-resistant schizophrenia is taken to indicate a lack of satisfactory clinical improvement despite dual treatment with antipsychotics of adequate dosage and duration.
[0028] Pharmaceutical Compositions The pharmaceutical compositions may be specifically formulated for administration by any suitable route, including oral, rectal, intranasal, buccal, sublingual, transdermal, and parenteral (e.g., subcutaneous, intramuscular, and intravenous) routes. The oral route is preferred.
[0029] It will be appreciated that the route will depend on the general condition and age of the subject to be treated, the nature of the condition to be treated, and the active ingredient.
[0030] In the present context, the term "excipient" or "pharmaceutical acceptable excipient" refers to pharmaceutical excipients including, but not limited to, fillers, anti-adherents, binders, coatings, colorants, disintegrants, flavors, glidants, lubricants, preservatives, adsorbents, sweeteners, solvents, vehicles, and auxiliary agents.
[0031] The present invention also provides pharmaceutical compositions comprising 4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1,2,2-trimethylpiperazine prodrugs (1a and 1b) or 4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d3)piperazine prodrugs (2a and 2b) or pharma- ceutically acceptable salts thereof. The pharmaceutical compositions according to the present invention are described in Remington, The Science and Practice of Pharmacy, 22 th The compositions can be formulated with pharmacopoeiasally acceptable excipients according to conventional techniques, such as those disclosed in Allen, Loyd V., Jr. (Ed.), ed., edition (2012).
[0032] Pharmaceutical compositions for oral administration include solid oral dosage forms, such as tablets, capsules, powders, and granules; and liquid oral dosage forms, such as solutions, emulsions, suspensions, and syrups, as well as powders and granules to be dissolved or suspended in a suitable liquid.
[0033] The solid oral dosage forms may be presented as discrete units (e.g., tablets or hard or soft capsules), each containing a predetermined amount of active ingredient and preferably one or more suitable excipients. Where appropriate, the solid dosage forms may be prepared with coatings, such as enteric coatings, or they may be formulated to provide a controlled release of the active ingredient, such as delayed or extended release, according to methods well known in the art. Where appropriate, the solid dosage forms may be in the form of disintegration in saliva, such as, for example, oral dispersible tablets.
[0034] Examples of excipients suitable for solid oral formulations include, but are not limited to, microcrystalline cellulose, corn starch, lactose, mannitol, povidone, croscarmellose sodium, sucrose, cyclodextrin, talc, gelatin, pectin, magnesium stearate, stearic acid, and lower alkyl ethers of cellulose.Similarly, solid formulations may contain excipients for delayed or extended release formulations known in the art, such as glyceryl stearate or hypromellose.
[0035] When a solid material is used for oral administration, the formulation can be prepared, for example, by mixing the active ingredient with a solid excipient and then compressing the mixture in a conventional tablet machine, or the formulation can be placed, for example, in powder, pellet, or minitablet form, for example, into a hard capsule. The amount of solid excipient will vary widely but will typically range from about 25 mg to about 1 g per dosage unit.
[0036] Liquid oral dosage forms can be presented as, for example, elixirs, syrups, oral drops, or liquid-filled capsules. Liquid oral dosage forms can also be presented as powders for solution or suspension in aqueous or non-aqueous liquids. Examples of excipients suitable for liquid oral preparations include, but are not limited to, ethanol, propylene glycol, glycerol, polyethylene glycol, poloxamer, sorbitol, polysorbates, mono- and diglycerides, cyclodextrin, coconut oil, palm oil, and water. Liquid oral dosage forms can also be prepared, for example, by dissolving or suspending the active ingredient in an aqueous or non-aqueous liquid, or by incorporating the active ingredient into an oil-in-water or water-in-oil liquid emulsion.
[0037] Additional excipients such as colorants, flavoring agents, and preservatives may be used in both solid and liquid oral formulations.
[0038] Pharmaceutical compositions for parenteral administration include sterile aqueous and non-aqueous solutions, dispersions, suspensions, or emulsions for injection or infusion, concentrates for injection or infusion, and sterile powders to be reconstituted before use into sterile solutions or dispersions for injection or infusion. Examples of excipients suitable for parenteral formulations include, but are not limited to, water, coconut oil, palm oil, and cyclodextrin solutions. Aqueous formulations should preferably be buffered if necessary and rendered isotonic with sufficient saline or glucose.
[0039] Other types of pharmaceutical compositions include suppositories, inhalants, creams, gels, skin patches, implants, and formulations for buccal or sublingual administration.
[0040] Excipients used in pharmaceutical formulations should be suitable for the intended route of administration and compatible with the active ingredient.
[0041] EMBODIMENTS OF THE PRESENT DISCLOSURE The present invention is further described in the following embodiments:
[0042] 1. Prodrugs of 4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1,2,2-trimethylpiperazine (in the forms 1a and 1b) or 4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d3)piperazine (in the forms 1a and 1b) [ka] (In the formula, X - is a halide anion such as chloride, bromide, or iodide, an optionally fluorinated C1-C aryl anion such as mesylate, tosylate, trifluoromethanesulfonate, or nonafluorobutanesulfonate; 10 Optionally fluorinated linear or branched C1-C aryl groups such as sulfonates and trifluoroacetates. 11carboxylate); or a pharma- ceutically acceptable salt thereof.
[0043] 2. R is a linear or branched C1-C 11 Alkyl and C3-C 10 The prodrug of embodiment 1, or a pharma- ceutically acceptable salt thereof, selected from the group consisting of: cycloalkyl.
[0044] 3. The prodrug or a pharma- ceutically acceptable salt thereof according to any of embodiments 1 and 2, wherein R is selected from the group consisting of methyl, tertbutyl, n-undecyl, and cyclohexylmethyl.
[0045] 4. The prodrug of any of embodiments 1-3, wherein the pharmaceutically acceptable salts are formed from hydrochloric acid, hydrobromic acid, phosphoric acid, nitrous acid, sulfuric acid, benzoic acid, citric acid, gluconic acid, lactic acid, maleic acid, succinic acid, tartaric acid, acetic acid, propionic acid, oxalic acid, maleic acid, fumaric acid, glutamic acid, pyroglutamic acid, salicylic acid, salicylic acid, saccharin, and sulfonic acids, such as methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, and benzenesulfonic acid.
[0046] 5. C1-C, each of which is an optionally fluorinated anion such as a halide anion, such as chloride, bromide, or iodide, mesylate, tosylate, trifluoromethanesulfonate, or nonafluorobutanesulfonate. 10 Optionally fluorinated linear or branched C1-C aryl groups such as sulfonates and trifluoroacetates. 11carboxylates, (R)-1-(acetoxymethyl)-4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1,2,2-trimethylpiperazin-1-ium, (S)-1-(acetoxymethyl)-4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1,2,2-trimethylpiperazin-1-ium, (R)-1-(acetoxymethyl)-4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1,2,2-trimethylpiperazin-1-ium, (Phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d3)piperazin-1-ium, (S)-1-(acetoxymethyl)-4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d3)piperazin-1-ium, (R)-4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-methyl-1-((pivaloyloxy)methyl) ethyl)piperazin-1-ium, (S)-4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-methyl-1-((pivaloyloxy)methyl)piperazin-1-ium, (R)-4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d3)-1-((pivaloyloxy)methyl)piperazin-1-ium, (S)-4-((1R,3S)-6-chloro-3-(phenyl -d5)-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d3)-1-((pivaloyloxy)methyl)piperazin-1-ium, (R)-4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1-((dodecanoyloxy)methyl)-1,2,2-trimethylpiperazin-1-ium, (S)-4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1-((dodecanoyloxy)methyl)-1,2,2-Trimethylpiperazin-1-ium, (R)-4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-1-((dodecanoyloxy)methyl)-2,2-dimethyl-1-(methyl-d3)piperazin-1-ium, (S)-4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden -1-yl)-1-((dodecanoyloxy)methyl)-2,2-dimethyl-1-(methyl-d3)piperazin-1-ium, (R)-4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1-((2-cyclohexylacetoxy)methyl)-1,2,2-trimethylpiperazin-1-ium, (S)-4-((1R,3S)-6-chloro -3-phenyl-2,3-dihydro-1H-inden-1-yl)-1-((2-cyclohexylacetoxy)methyl)-1,2,2-trimethylpiperazin-1-ium, (R)-4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-1-((2-cyclohexylacetoxy)methyl)-2,2-dimethyl-1-(methyl-d 3) The prodrug according to any one of embodiments 1 to 4, selected from the group consisting of piperazine-1-ium, (S)-4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-1-((2-cyclohexylacetoxy)methyl)-2,2-dimethyl-1-(methyl-d3)piperazine-1-ium; or a pharma-ceutically acceptable salt thereof.
[0047] 6. A pharmaceutical composition comprising any of the prodrugs of embodiments 1-5 or a pharma- ceutically acceptable salt thereof and one or more pharma- ceutically acceptable excipients.
[0048] 7. A compound according to any one of embodiments 1 to 5 or a pharma- ceutically acceptable salt thereof, or a pharmaceutical composition according to embodiment 6, for use in therapy.
[0049] 8. Use of a compound according to any one of embodiments 1 to 5 or a salt thereof, or a pharmaceutical composition according to embodiment 6, for the manufacture of a medicament for the treatment of a central nervous system (CNS) disease.
[0050] 9. A compound according to any one of embodiments 1 to 5 or a pharmaceutical composition according to embodiment 6 for use in a method for the treatment of a CNS disorder.
[0051] 10. A method for the treatment of a CNS disorder, comprising the administration of a therapeutically effective amount of a compound according to any of embodiments 1 to 5 or a pharmaceutical composition according to embodiment 6 to a patient in need thereof. EXAMPLES
[0052] Compounds of the Invention The compounds of the present invention can be prepared from either 4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1,2,2-trimethylpiperazine (1) or 4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d3)piperazine (2), both of which have been described in the prior art as discussed above: [ka]
[0053] These compounds can be alkylated at the non-benzylic piperazine nitrogen atom by treatment with alkylating agent 3, either directly or via in situ Finkelstein displacement of Y with a more reactive halogen, such as conversion of Y=Cl to Y=I by addition of sodium iodide or conversion of Y=Cl to Y=Br by addition of tetra-n-butylammonium bromide or sodium bromide. The reaction will give the mixture of N-diastereoisomers 1a / 1b or 2a / 2b, depending on whether 1 or 2 is used as substrate. These N-diastereoisomers can be separated by recrystallization and / or chiral chromatography, utilizing either high performance liquid chromatography (HPLC), supercritical fluid chromatography (SFC), or simulated moving bed chromatography (SMB). For example, the anion Y can be separated using ion exchange resins. - X - It can be exchanged for Y - is the previously defined X - The order of the last two operations may be reversed and both steps may be carried out several times. The alkylating agents 3 are commercially available, such as 3b from CombiBlocks (catalog number QC-7757), or are described in the specification for 3a or can be prepared in a similar manner as described in the literature (for sulfonates, see for example WO 2012 / 137225).
[0054] Methods Used to Prepare Prodrugs of the Invention The following methods were utilized for high performance liquid chromatography (HPLC), liquid chromatography / mass spectrometry (LC / MS), supercritical fluid chromatography (SFC), and ion exchange.
[0055] Method 1: HPLC was performed on an Agela-HP-q-p600 instrument equipped with an Agela Innoval ods 250 x 80 mm column (10 micron particle size; column temperature 20°C). Eluent: 0.05% aqueous HCl / acetronitrile 4:1-1:1 over 20 min at a flow rate of 150 mL / min.
[0056] Method 2: LC / MS was performed on an Agilent 1200 & 1956A Instrument equipped with a Phenomenex Luna C18(2) 50x2mm column (5 micron particle size; column temperature 40°C). Eluent: 0.037% trifluoroacetic acid in water / 0.018% trifluoroacetic acid in acetonitrile at a flow rate of 0.6mL / min 1:0 for 0.8 min; 1:0-2:3 over 6.2 min; 2:3 over 3 min; 2:3-1:0 over 0.1 min.
[0057] Method 3: HPLC was performed on an Agela-HP-q-p600 instrument equipped with a Phenomenex Luna C18 250 x 50 mm column (10 micron particle size; column temperature 20 °C). Eluent: 0.05% aqueous HCl / acetonitrile 4:1-1:1 over 20 min at a flow rate of 80 mL / min.
[0058] Method 4: SFC was performed by stack injection on a Thar SFC80 prep instrument equipped with a Chiralpak AD-H 250x30mm column (5 micron particle size) operating at 40°C. Eluent: CO2 / 0.1% trifluoroacetic acid in methanol 7:3 for 5 min at a flow rate of 70g / min. System back pressure 100 bar.
[0059] Method 5: SFC was performed on a Thar Analytical SFC instrument equipped with a Chiralpak AD-3 100 x 4.6 mm column (particle size 3 microns; column temperature 40 °C). Eluent: 0.05% isopropylamine in CO2 / methanol 95:5-3:2 over 5 min at a flow rate of 4.0 mL / min. System back pressure 100 bar.
[0060] Method 6: SFC was performed as method 4 with a runtime of 7 minutes.
[0061] Method 7: LC / MS was performed on an Agilent 1200 & MS 1956A Instrument equipped with a Phenomenex Luna C18(2) 50x2mm column (5 micron particle size; column temperature 40°C). Eluent: 0.037% trifluoroacetic acid in water / 0.018% trifluoroacetic acid in acetonitrile at a flow rate of 0.8mL / min 9:1 for 0.4 min; 9:1-0:1 over 3.0 min; 0:1 for 0.45 min; 0:1-9:1 over 0.01 min; 9:1 for 0.64 min.
[0062] Method 8: HPLC was performed as in method 3 with an eluent gradient of 3:2-3:7 over 20 min.
[0063] Method 9: SFC was performed on a Thar SFC80 prep instrument equipped with a Chiralpak AD-H 250x30mm column (5 micron particle size; column temperature 40°C) by stack injection. Eluent: CO2 / 0.1% trifluoroacetic acid in methanol 4:1 for 6 min at a flow rate of 70 g / min. System back pressure 100 bar.
[0064] Method 10: SFC was performed on a Waters Acquity UPC2 instrument equipped with a Chiralpak AD-3 150 x 4.6 mm column (particle size 3 microns; column temperature 35°C). Eluent: 0.05% isopropylamine in CO2 / methanol 3:2 over 6 or 10 min at a flow rate of 2.5 mL / min. System back pressure 1500 psi.
[0065] Method 11: Ion exchange was performed using anion exchange resin in the chloride form (717; Domestic 10024160) ion exchange resin. The sample was dissolved in a 1:1 mixture of acetonitrile and water, and the solution was slowly run through a column packed with resin (using approximately 6 times the amount of resin and sample). Acetonitrile / water (1:1) was added until the entire sample was eluted. The combined product fractions were concentrated in vacuo and lyophilized to give the chloride salt of the compound.
[0066] Method 12: LC / MS was performed on an Agilent 1200 & MS 1956A Instrument equipped with a Phenomenex Luna C18(2) 50x2mm column (5 micron particle size; column temperature 40°C). Eluent: 0.037% trifluoroacetic acid in water / 0.018% trifluoroacetic acid in acetonitrile at a flow rate of 0.8mL / min 99:1-1:9 over 3.4 min; 1:9-0:1 over 0.45 min; 0:1-99:1 over 0.01 min; 991:1 over 0.64 min.
[0067] Method 13: LC / MS was performed on an Agilent 1200 & MS 1956A Instrument equipped with a Phenomenex Luna C18(2) 50x2mm column (5 micron particle size; column temperature 40°C). Eluent: 0.037% trifluoroacetic acid in water / 0.018% trifluoroacetic acid in acetonitrile at a flow rate of 0.8mL / min 3:2-0:1 over 3.4 min; 0:1 over 0.45 min; 0:1-3:2 over 0.01 min; 3:2 over 0.64 min.
[0068] Method 14: LC / MS was performed on an Agilent 1200 & MS 6120 Instrument equipped with a Phenomenex Luna C18(2) 50 x 2 mm column (5 micron particle size; column temperature 40 °C). Eluent: 0.037% trifluoroacetic acid in water / 0.018% trifluoroacetic acid in acetonitrile at a flow rate of 0.8 mL / min 3:1-0:1 over 3.4 min; 0:1 for 0.45 min; 0:1-3:1 over 0.01 min; 3:1 for 0.64 min.
[0069] Method 15: LC / MS was performed on an Agilent 1200 & MS 6120B Instrument equipped with a Phenomenex Luna C18(2) 50 x 2 mm column (5 micron particle size; column temperature 40 °C). Eluent: 0.037% trifluoroacetic acid in water / 0.018% trifluoroacetic acid in acetonitrile at a flow rate of 0.8 mL / min 9:1-1:4 over 4.0 min; 1:4 for 2.0 min; 1:4-9:1 over 0.01 min; 9:1 for 2.0 min.
[0070] Method 16: SFC was performed as method 9 with a runtime of 8 minutes.
[0071] Method 17: LC / MS was performed on an Agilent 1200 & MS 1956A Instrument equipped with a Phenomenex Luna C18(2) 50 x 2 mm column (5 micron particle size; column temperature 40 °C). Eluent: 0.037% trifluoroacetic acid in water / 0.018% trifluoroacetic acid in acetonitrile at a flow rate of 0.8 mL / min 1:0 for 0.8 min; 1:0-2:3 over 6.2 min; 2:3 over 3 min; 2:3-1:0 over 0.1 min.
[0072] Method 18: Reverse phase column chromatography was performed on a Biotage One instrument equipped with an Agela 40 x 10 cm (20-40 nM) C18 column at 25° C. Eluent: water and 0.4% concentrated hydrochloric acid 7:3-3:7 over 30 min; 3:7 for 25 min; 0:1 for 10 min at a flow rate of 120 mL / min.
[0073] Example 1: Preparation of iodomethyl acetate (alkylating agent 3a) [ka] To a mixture of NaI (29.0 g) and acetonitrile (140 mL) was added chloromethyl acetate (3a1; 20.0 g) dropwise at 20° C. in the dark. The reaction was stirred at ambient temperature for 24 h. The resulting mixture was partitioned between methyl tert-butyl ether (MTBE; 160 mL) and water (200 mL), and the aqueous layer was extracted with MTBE (150 mL). The combined organic layer was washed successively with saturated aqueous sodium bicarbonate (200 mL), 10 percent aqueous sodium sulfite (200 mL), and saturated aqueous sodium chloride (100 mL), before it was dried over sodium sulfate, filtered, and concentrated to give iodomethyl acetate (3a; 15.5 g) sufficiently pure for the next step.
[0074] Example 2: Preparation of iodomethyl n-dodecanoate (alkylating agent 3c) [ka] n-Dodecanoyl chloride (3c2; 80.0 g) was slowly added to a mixture of paraformaldehyde (22.0 g) and zinc chloride (24.9 g) in acetonitrile (550 mL) at -10°C under argon atmosphere. The reaction mixture was stirred at this temperature for 1 h and at ambient temperature for 18 h. The crude reaction mixture was directly purified by column flash chromatography on silica gel (gradient eluent: petroleum ether / ethyl acetate 50 / 1-2 / 1) to give n-chloromethyl dodecanoate (3c1; 45.4 g) sufficiently pure for the next step. Compound 3c1 (45.0 g) was added dropwise to a mixture of sodium iodide (32.5 g) in acetonitrile (300 mL) at ambient temperature in the dark. The reaction was stirred at ambient temperature for 24 h. The crude mixture was partitioned between MTBE (300 mL) and water (300 mL), and the aqueous layer was extracted with MTBE (100 mL). The combined organic layer was washed successively with saturated aqueous sodium bicarbonate (200 mL), 10 percent aqueous sodium sulfite (150 mL), and saturated aqueous sodium chloride (150 mL), before it was dried over sodium sulfate, filtered, and concentrated to give iodomethyl n-dodecanoate (3c; 51.0 g) sufficiently pure for the next step.
[0075] Example 3: Preparation of iodomethyl 2-cyclohexylacetate (alkylating agent 3d) [ka] Thionyl chloride (69 mL) was added to a solution of 2-cyclohexylacetic acid (3d3; 44.8 g) in toluene (180 mL) under argon and the mixture was stirred at 110° C. for 12 h. The volatiles were removed in vacuo to give 2-cyclohexylacetyl chloride (3d2; 42.3 g) sufficiently pure for the next step. 2-Cyclohexylacetyl chloride (3d2; 48.6 g - material combined from another batch from the previous step) was added to a solution of zinc chloride (20.6 g) and paraformaldehyde (18.2 g) in acetonitrile (336 mL) at -10° C. under argon. The reaction mixture was stirred at -10° C. for 1 h and then at ambient temperature for 18 h. The volatiles were removed in vacuo. The residue was purified by column flash chromatography on silica gel (gradient eluent: petroleum ether / ethyl acetate 1 / 0-0 / 1) to give 2-cyclohexyl chloromethyl acetate (3d1; 24.0 g) sufficiently pure for the next step. 2-cyclohexylacetate (3d1; 21.9 g) was added dropwise to a solution of sodium iodide (18.1 g) in acetonitrile (126 mL) at ambient temperature in the dark. The reaction was stirred at ambient temperature for 24 h. The crude mixture was partitioned between MTBE (200 mL) and water (200 mL) and the aqueous layer was extracted with MTBE (150 mL). The combined organic layers were washed successively with saturated aqueous sodium bicarbonate (200 mL), 10 percent aqueous sodium sulfite (200 mL), and saturated aqueous sodium chloride (100 mL) before it was dried over sodium sulfate, filtered, and concentrated to give iodomethyl 2-cyclohexylacetate (3d; 27.0 g) sufficiently pure for the next step.
[0076] Example 4: Preparation of acetoxymethyl 1a and 1b [ka] A solution of 4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1,2,2-trimethylpiperazine (1; 6.0 g) in acetonitrile (42 mL) was heated to 80° C. before adding methyl iodoacetate (3a; 6.76 g). The mixture was stirred at 80° C. for 1 h before removing the volatiles in vacuo. The remaining solid was suspended in MTBE (25 mL) and then filtered off. The filter cake was washed with MTBE (15 mL) and dried to give approximately 8 g of (R)-1-(acetoxymethyl)-4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1,2,2-trimethylpiperazin-1-ium iodide (1a1; X=I - ) and (S)-1-(acetoxymethyl)-4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1,2,2-trimethylpiperazin-1-ium iodide (1b1; X=I - ) which was converted from the iodide salt to the corresponding chloride salt by ion exchange (Method 11) to give 1a1; X=Cl. - and 1b1; X=Cl - This material was purified by preparative HPLC (Method 1) to give the crude chloride salt of (R)-1-(acetoxymethyl)-4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1,2,2-trimethylpiperazin-1-ium chloride and (S)-1-(acetoxymethyl)-4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1,2,2-trimethylpiperazin-1-ium chloride (1a1; X=Cl). - and 1b1; X=Cl - ;3g) to give a mixture. 1H NMR: 400 MHz methanol-d 47.56 (broad s, 1H), 7.29 (t, J = 7.2 Hz, 3H), 7.25-7.18 (m, 1H), 7.14-7.09 (m, 2H), 6.96 (d, J = 7.9 Hz, 1H), 5.50 (broad s, 1H), 5.44-5.33 (m, 1H), 4.72 (broad s, 1H), 4.60-4.48 (m, 1H), 3.78 (broad d, J = 5.7 Hz, 1H), 3.66 (broad s, 1H), 3.19-2.81 (m, 8H), 2.26 (s, 4H), 1.71-1.57 (m, 6H). LC / MS (Method 17): retention time 6.60 min, UV purity (220 nm) 86.5%, m / z observed mass 427.1.
[0077] Example 5: Preparation of acetoxymethyl 2a and 2b [ka] (R)-1-(acetoxymethyl)-4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d3)piperazin-1-ium iodide and (S)-1-(acetoxymethyl)-4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d3)piperazin-1-ium iodide (2a1; X=I - and 2b1;X=I - ) and (R)-1-(acetoxymethyl)-4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d3)piperazin-1-ium chloride and (S)-1-(acetoxymethyl)-4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d3)piperazin-1-ium chloride (2a1; X=Cl - and 2b1; X=Cl -A mixture of (R)-1-(acetoxymethyl)-4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d3)piperazine (2; 6.50 g) and methyl iodoacetate (3a; 7.16 g) in acetonitrile (45.0 mL) was prepared in a manner similar to that of 1a1 and 1b1. The synthesis started with 4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d3)piperazine (2; 6.50 g) and methyl iodoacetate (3a; 7.16 g) in acetonitrile (45.0 mL), yielding approximately 8 g of crude iodide and 2.00 g of (R)-1-(acetoxymethyl)-4-((1R,3S)-6-chloro -3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d3)piperazin-1-ium chloride and (S)-1-(acetoxymethyl)-4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d3)piperazin-1-ium chloride (2a1; X=Cl - and 2b1; X=Cl - ) was purified by HPLC (Method 1) to give the mixture. 1 H NMR: 400 MHz methanol-d 47.61-7.54 (m, 1H), 7.34-7.28 (m, 1H), 6.96 (d, J = 8.3 Hz, 1H), 5.51 (broad d, J = 12.7 Hz, 1H), 5.47-5.35 (m, 1H), 4.74 (broad s, 1H), 4.56 (broad s, 1H), 3.77 (broad s, 1H), 3.68 (broad s, 1H), 3.27-2.78 (m, 5H), 2.26 (d, J = 0.9 Hz, 4H), 1.73-1.58 (m, 6H). LC / MS (Method 17): retention time 6.56 min, UV purity (220 nm) 93.5%, m / z observed mass 435.2.
[0078] Example 6: Preparation of pivaloyloxymethyl 1a and 1b [ka] (R)-4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1,2,2-trimethyl-1-((pivaloyloxy)methyl)piperazin-1-ium iodide and (S)-4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1,2,2-trimethyl-1-((pivaloyloxy)methyl)piperazin-1-ium iodide (1a2; X=I - and 1b2;X=I - ) and (R)-4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1,2,2-trimethyl-1-((pivaloyloxy)methyl)piperazin-1-ium chloride and (S)-4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1,2,2-trimethyl-1-((pivaloyloxy)methyl)piperazin-1-ium chloride (1a2; X=Cl - and 1b2; X=Cl - A mixture of (R)-4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1,2,2-trimethylpiperazine (1; 4.6 g) and iodomethyl pivalate (3b; 6.27 g) in acetonitrile (32 mL) was prepared in a manner similar to 1a1 and 1b1. The synthesis started with 4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1,2,2-trimethylpiperazine (1; 4.6 g) and iodomethyl pivalate (3b; 6.27 g) in acetonitrile (32 mL) to give approximately 5 g of crude iodide and approximately 4 g of (R)-4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro -1H-inden-1-yl)-2,2-dimethyl-1-methyl-1-((pivaloyloxy)methyl)piperazin-1-ium chloride and (S)-4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-methyl-1-((pivaloyloxy)methyl)piperazin-1-ium chloride (1a2; X=Cl) - and 1b2; X=Cl - ) was purified by HPLC (Method 3) to give a mixture of 1,2-dichloro-2,3-diphenyl-2,4-diphenyl-1,2 ... First eluted isomer: 1.00 g of (R)-4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1,2,2-trimethyl-1-((pivaloyloxy)methyl)piperazin-1-ium chloride (1a2; X=Cl - ) or (S)-4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1,2,2-trimethyl-1-((pivaloyloxy)methyl)piperazin-1-ium chloride (1b2; X=Cl - ) either 1 H NMR: 400MHz methanol-d 47.71 (broad s., 1H), 7.39-7.27 (m, 3H), 7.26-7.19 (m, 1H), 7.18-7.10 (m, 2H), 6.97 (d, J = 8.4Hz, 1H), 5.70-5.57 (m, 1H), 5.52 (d, J = 8.8Hz, 1H), 4.93 (broad s., 1H), 4.69 (t, J = 7.6Hz, 1H), 3.85 (broad s., 2H), 3.50-3.31 (m, 4H), 3.16 (s, 3H), 3.05-2.92 (m, 1H), 2.42-2.28 (m, 1H), 1.71 (broad s, 6H), 1.31 (s, 9H). LC / MS (Method 12): retention time 3.12 min, UV purity (220 nm) 98.5%, m / z observed mass 469.2. SFC (Method 5): Retention time 1.91 min, UV purity (220 nm) >99%. Second eluting isomer: 0.80 g of (S)-4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1,2,2-trimethyl-1-((pivaloyloxy)methyl)piperazin-1-ium chloride (1b2; X=Cl - ) or (R)-4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1,2,2-trimethyl-1-((pivaloyloxy)methyl)piperazin-1-ium chloride (1a2; X=Cl - ) either 1H NMR: 400 MHz methanol-d 47.69 (broad s., 1H), 7.37-7.26 (m, 3H), 7.26-7.18 (m, 1H), 7.14 (d, J = 7.2 Hz, 2H), 6.96 (d, J = 8.4 Hz, 1H), 5.58-5.40 (m, 2H), 4.90 (broad s., 1H), 4.65 (broad s., 1H), 3.94 (broad s., 1H), 3.70 (d, J = 14.0 Hz, 1H), 3.36 (broad s., 3H), 3.22 (broad s., 3H), 3.16-2.90 (m, 2H), 2.39-2.25 (m, 1H), 1.79-1.56 (m, 6H), 1.31 (s, 9H). LC / MS (Method 7): retention time 2.72 min, UV purity (220 nm) 97%, m / z observed mass 469.2. SFC (Method 5): Retention time 2.36 min, UV purity (220 nm) >96%.
[0079] Example 7: Preparation of pivaloyloxymethyl 2a and 2b [ka] (R)-4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d3)-1-((pivaloyloxy)methyl)piperazin-1-ium iodide and (S)-4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d3)-1-((pivaloyloxy)methyl)piperazin-1-ium iodide (2a2; X=I - and 2b2;X=I -) and (R)-4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d3)-1-((pivaloyloxy)methyl)piperazin-1-ium chloride and (S)-4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d3)-1-((pivaloyloxy)methyl)piperazin-1-ium chloride (2a2; X=Cl - and 2b2; X=Cl - A mixture of (R)-4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d3)piperazine (2; 6.00 g) and iodomethyl pivalate (3b; 8.00 g) in acetonitrile (42 mL) was prepared in a manner similar to 1a1 and 1b1. The synthesis began with 4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d3)piperazine (2; 6.00 g) and iodomethyl pivalate (3b; 8.00 g) in acetonitrile (42 mL), yielding approximately 5 g of crude iodide and approximately 4 g of (R)-4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro- d-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d3)-1-((pivaloyloxy)methyl)piperazin-1-ium chloride and (S)-4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d3)-1-((pivaloyloxy)methyl)piperazin-1-ium chloride (2a2; X=Cl) - and 2b2; X=Cl - ) was purified by HPLC (Method 3) to give a mixture of 1,2-dichloro-2,3-dichloro-2,4-dichloro-2,5-dichloro-2,6-dichloro-2,7-dichloro-2,8-dichloro-2,9-dichloro-2,8-dichloro-2,9-dichloro-2,9-dichloro-2,9-dichloro-2,1 ... First eluted isomer: 1.00 g of (R)-4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d3)-1-((pivaloyloxy)methyl)piperazin-1-ium chloride (2a2; X=Cl -) or (S)-4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d3)-1-((pivaloyloxy)methyl)piperazin-1-ium chloride (2b2; X=Cl - ) either 1 H NMR: 400 MHz methanol-d 47.71 (broad s, 1H), 7.36 (dd, J = 2.0, 8.1 Hz, 1H), 6.97 (d, J = 7.9 Hz, 1H), 5.61 (broad s, 1H), 5.52 (d, J = 8.8 Hz, 1H), 5.00-4.89 (m, 1H), 4.68 (s, 1H), 3.85 (broad s, 2H), 3.54-3.31 (m, 3H), 3.28-3.16 (m, 1H), 2.99 (broad dd, J = 10.3, 13.8 Hz, 1H), 2.43-2.28 (m, 1H), 1.71 (broad s, 6H), 1.32 (s, 9H). LC / MS (Method 7): retention time 2.72 min, UV purity (220 nm) 98.9%, m / z observed mass 477.3. SFC (Method 5): Retention time 1.79 min, UV purity (220 nm) >99%. The second eluting isomer: 0.72 g of (S)-4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d3)-1-((pivaloyloxy)methyl)piperazin-1-ium chloride (2b2; X=Cl - ) or (R)-4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d3)-1-((pivaloyloxy)methyl)piperazin-1-ium chloride (2a2; X=Cl - ) either 1H NMR: 400MHz methanol-d 47.44 (d, J = 2.2Hz, 1H), 7.25 (dd, J = 2.0, 8.1Hz, 1H), 6.94 (d, J = 8.3Hz, 1H), 5.52-5.45 (m, 1H), 5.45-5.39 (m, 1H), 4.58 (dd, J = 3.9, 7.9Hz, 1H), 4.46 (t, J = 7.7Hz, 1H), 3.74 (broad s, 1H), 3.53 (broad d, J = 12.7Hz, 1H), 3.09-2.74 (m, 4H), 2.63 (broad s, 1H), 2.21-2.04 (m, 1H), 1.69-1.48 (m, 6H), 1.38-1.24 (m, 9H). LC / MS (Method 7): retention time 2.72 min, UV purity (220 nm) 97.6%, m / z observed mass 477.3. SFC (method 5): retention time 2.1 min, UV purity (220 nm) >97%.
[0080] Example 8: Preparation of dodecanoyloxymethyl 1a and 1b [ka] (R)-4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1-((dodecanoyloxy)methyl)-1,2,2-trimethylpiperazin-1-ium iodide and (S)-4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1-((dodecanoyloxy)methyl)-1,2,2-trimethylpiperazin-1-ium iodide (1a3; X=I - and 1b3;X=I - ) and (R)-4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1-((dodecanoyloxy)methyl)-1,2,2-trimethylpiperazin-1-ium chloride and (S)-4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1-((dodecanoyloxy)methyl)-1,2,2-trimethylpiperazin-1-ium chloride (1a3; X=Cl - and 1b3; X=Cl- A mixture of 1a1 and 1b1 was prepared in a manner similar to that of 1a1 and 1b1. The synthesis began with 4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1,2,2-trimethylpiperazine (1; 7.00 g) and iodomethyl dodecanoate (3c; 16.8 g) in acetonitrile (49 mL) to give approximately 5.5 g of crude iodide. This material was purified by reverse phase column chromatography (Method 18) followed by ion exchange (Method 11) to give 3.2 g of (R)-4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1-((dodecanoyloxy)methyl)-1,2,2-trimethylpiperazin-1-ium chloride and (S)-4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1-((dodecanoyloxy)methyl)-1,2,2-trimethylpiperazin-1-ium chloride (1a3; X=Cl). - and 1b3; X=Cl - ) mixture. 1 H NMR: 400MHz methanol-d 47.45 (s, 1H), 7.31-7.23 (m, 3H), 7.23-7.17 (m, 1H), 7.13-7.07 (m, 2H), 6.94 (d, J = 8.3Hz, 1H), 5.52 (broad s, 1H), 5.40 (dd, J = 3.9, 8.8Hz, 1H), 4.64-4.55 (m, 1H), 4.47 (broad t, J = 7.2Hz, 1H), 3. 81-3.64(m,1H), 3.56(broad d, J=14.5Hz,1H), 3.11(d, J=7.5Hz,3H), 3.04-2.91(m,2H), 2.86-2.75(m,2H), 2.57(dt, J=1.8,7.5Hz,2H), 2.19-2.06(m,1H), 1.71-1.56(m,8H), 1.29(broad s,17H), 0.93-0.84(m,3H). LC / MS (Method 13): retention time 2.66 min, UV purity (220 nm) 99.3%, m / z observed mass 567.3.
[0081] Example 9: Preparation of dodecanoyloxymethyl 2a and 2b [ka] (R)-4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-1-((dodecanoyloxy)methyl)-2,2-dimethyl-1-(methyl-d3)piperazin-1-ium iodide and (S)-4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-1-((dodecanoyloxy)methyl)-2,2-dimethyl-1-(methyl-d3)piperazin-1-ium iodide (2a3; X=I - and 2b3;X=I - ) and (R)-4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-1-((dodecanoyloxy)methyl)-2,2-dimethyl-1-(methyl-d3)piperazin-1-ium chloride and (S)-4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-1-((dodecanoyloxy)methyl)-2,2-dimethyl-1-(methyl-d3)piperazin-1-ium chloride (2a3; X=Cl - and 2b3; X=Cl -A mixture of (R)-4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d3)piperazine (2; 5.60 g) and methyl dodecanoate (3c; 10.5 g) in acetonitrile (39 mL) gave approximately 5 g of crude iodide and 3.1 g of (R)-4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d3)piperazine. d-1H-inden-1-yl)-1-((dodecanoyloxy)methyl)-2,2-dimethyl-1-(methyl-d3)piperazin-1-ium chloride and (S)-4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-1-((dodecanoyloxy)methyl)-2,2-dimethyl-1-(methyl-d3)piperazin-1-ium chloride (2a3; X=Cl) - and 2b3; X=Cl - ) mixture. 1 H NMR: 400MHz methanol-d 47.49 (broad s, 1H), 7.27 (d, J=8.3Hz, 1H), 6.94 (d, J=8.3Hz, 1H), 5.52 (broad s, 1H), 5.46-5.36 (m, 1H), 4.69-4.58 (m, 1H), 4.50 (broad t, J=7.5Hz, 1H), 3.86-3.66 (m, 1H), 3.61 (broad s, 1H), 3.16-2.79 (m, 4H), 2.57 (dt, J=1.3, 7.5Hz, 2H), 2.23-2.07 (m, 1H), 1.76-1.51 (m, 8H), 1.47-1.19 (m, 17H), 0.95-0.83 (m, 3H). LC / MS (Method 13): retention time 2.68 min, UV purity (220 nm) 98.9%, m / z observed mass 575.4.
[0082] Example 10: Preparation of cyclohexylacetoxymethyl 1a and 1b [ka] (R)-4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1-((2-cyclohexylacetoxy)methyl)-1,2,2-trimethylpiperazin-1-ium iodide and (S)-4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1-((2-cyclohexylacetoxy)methyl)-1,2,2-trimethylpiperazin-1-ium iodide (1a4; X=I - and 1b4;X=I - ) and (R)-4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1-((2-cyclohexylacetoxy)methyl)-1,2,2-trimethylpiperazin-1-ium chloride and (S)-4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1-((2-cyclohexylacetoxy)methyl)-1,2,2-trimethylpiperazin-1-ium chloride (1a4; X=Cl - and 1b4; X=Cl - A mixture of (R)-4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1,2,2-trimethylpiperazine (1, 6.00 g) and iodomethyl 2-cyclohexylacetate (3d; 11.9 g) in acetonitrile (42 mL) gave approximately 8 g of crude iodide and 3.2 g of (R)-4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1,2,2-trimethylpiperazine (1, 6.00 g). 1H-inden-1-yl)-1-((2-cyclohexylacetoxy)methyl)-1,2,2-trimethylpiperazin-1-ium chloride and (S)-4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1-((2-cyclohexylacetoxy)methyl)-1,2,2-trimethylpiperazin-1-ium chloride (1a4; X=Cl) - and 1b4; X=Cl -) was purified by HPLC (Method 8) to give a mixture of 1,2-dichlorophenyl ether (Method 9). This mixture was separated by chiral SFC (Method 9). The two products were purified as above using Methods 11 and 8 to give two products: First eluted isomer: 1.00 g of (R)-4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1-((2-cyclohexylacetoxy)methyl)-1,2,2-trimethylpiperazin-1-ium chloride (1a4; X=Cl - ) or (S)-4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1-((2-cyclohexylacetoxy)methyl)-1,2,2-trimethylpiperazin-1-ium chloride (1b4; X=Cl - ) either 1 H NMR: 400MHz methanol-d 47.57 (broad s, 1H), 7.32-7.26 (m, 3H), 7.25-7.19 (m, 1H), 7.15-7.09 (m, 2H), 6.95 (d, J = 8.3Hz, 1H), 5.56 (broad s, 1H), 5.45 (d, J = 8.8Hz, 1H), 4.74 (broad s, 1H) ,4.57(broad t,J=7.5Hz,1H),3.84-3.60(m,2H),3.27-2.77(m,8H),2.46(d,J=7.0Hz,2H) ,2.23(td,J=7.2,14.5Hz,1H),1.99-1.47(m,12H),1.39-1.13(m,3H),1.12-0.96(m,2H) LC / MS (Method 14): retention time 2.85 min, UV purity (220 nm) 97.4%, m / z observed mass 509.3. SFC (method 10): retention time 2.45 minutes, UV purity (220 nm) >99%. The second eluting isomer: 0.33 g of (S)-4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1-((2-cyclohexylacetoxy)methyl)-1,2,2-trimethylpiperazin-1-ium chloride (1b4; X=Cl -) or (R)-4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1-((2-cyclohexylacetoxy)methyl)-1,2,2-trimethylpiperazin-1-ium chloride (1a4; X=Cl - ) either 1 H NMR: 400MHz methanol-d 47.51 (s, 1H), 7.33-7.26 (m, 3H), 7.25-7.19 (m, 1H), 7.14-7.09 (m, 2H), 6.96 (d, J = 8.8Hz, 1H), 5.56-5.47 (m, 1H), 5.46-5.39 (m, 1H), 4.72-4.64 (m, 1H), 4.52 (broad t, J=7.7Hz, 1H), 3.79(broad s, 1H), 3.62(broad s, 1H), 3.21-2.77(m, 8H), 2.46(d, J=6.8Hz, 2H), 2.26-2.12(m, 1H), 1.85-1.55(m, 12H), 1.43-1.16(m, 3H), 1.12-0.97(m, 2H). LC / MS (Method 15): retention time 3.66 min, UV purity (220 nm) 97.7%, m / z observed mass 509.2. SFC (Method 10): Retention time 6.41 min, UV purity (220 nm) >97%.
[0083] Example 11: Preparation of cyclohexylacetoxymethyl 2a and 2b [ka] (R)-4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-1-((2-cyclohexylacetoxy)methyl)-2,2-dimethyl-1-(methyl-d3)piperazin-1-ium iodide and (S)-4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-1-((2-cyclohexylacetoxy)methyl)-2,2-dimethyl-1-(methyl-d3)piperazin-1-ium iodide (2a4; X=I - and 2b4;X=I -) and (R)-4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-1-((2-cyclohexylacetoxy)methyl)-2,2-dimethyl-1-(methyl-d3)piperazin-1-ium chloride and (S)-4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-1-((2-cyclohexylacetoxy)methyl)-2,2-dimethyl-1-(methyl-d3)piperazin-1-ium chloride (2a4; X=Cl - and 2b4; X=Cl - A mixture of (R)-4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d3)piperazine (2; 6.00 g) and iodomethyl 2-cyclohexylacetate (3d; 11.7 g) in acetonitrile (42 mL) gave approximately 7.8 g of crude iodide and 6 g of (R)-4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro -1H-inden-1-yl)-1-((2-cyclohexylacetoxy)methyl)-2,2-dimethyl-1-(methyl-d3)piperazin-1-ium chloride and (S)-4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-1-((2-cyclohexylacetoxy)methyl)-2,2-dimethyl-1-(methyl-d3)piperazin-1-ium chloride (2a4; X=Cl - and 2b4; X=Cl - ) was purified by HPLC (Method 8) to give a mixture of 1,2-dichloro-2,3-dichloro-2,4-dichloro-2,5-dichloro-2,6-dichloro-2,7-dichloro-2,8-dichloro-2,9 ... First eluted isomer: 1.10 g of (R)-4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-1-((2-cyclohexylacetoxy)methyl)-2,2-dimethyl-1-(methyl-d3)piperazin-1-ium chloride (2a4; X=Cl -) or (S)-4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-1-((2-cyclohexylacetoxy)methyl)-2,2-dimethyl-1-(methyl-d3)piperazin-1-ium chloride (2b4; X=Cl - ) either 1 H NMR: 400MHz methanol-d 47.50 (broad s, 1H), 7.30 (broad d, J=8.2Hz, 1H), 6.97 (d, J=8.2Hz, 1H), 5.54 (broad s, 1H), 5.49-5.41 (m, 1H), 4.66 (broad s, 1H), 4.58-4.48 (m, 1H), 3.73 (broad s, 1H), 3.62 (broad s, 1H), 3.21-2.74 (m, 5H), 2.47 (d, J=6.8Hz, 2H), 2.26-2.12 (m, 1H), 1.92-1.57 (m, 12H), 1.38-1.17 (m, 3H), 1.14-0.98 (m, 2H). LC / MS (Method 14): retention time 2.68 min, UV purity (220 nm) 96.6%, m / z observed mass 517.2. SFC (Method 10): Retention time 2.33 min, UV purity (220 nm) >97%. The second eluting isomer: 1.10 g of (S)-4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-1-((2-cyclohexylacetoxy)methyl)-2,2-dimethyl-1-(methyl-d3)piperazin-1-ium chloride (2b4; X=Cl - ) or (R)-4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-1-((2-cyclohexylacetoxy)methyl)-2,2-dimethyl-1-(methyl-d3)piperazin-1-ium chloride (2a4; X=Cl - ) either 1H NMR: 400MHz methanol-d 47.48 (broad s, 1H), 7.28 (d, J = 8.2Hz, 1H), 6.95 (d, J = 8.2Hz, 1H), 5.49 (broad s, 1H), 5.44-5.38 (m, 1H), 4.64 (broad d, J = 4.0Hz, 1H), 4.49 (broad s, 1H), 3.83-3 .70(m,1H), 3.58(broad d, J=13.2Hz,1H), 3.16-2.63(m,5H), 2.45(d, J=6.8Hz,2H), 2.16(broad dd, J=6.9,10.7Hz,1H), 1.91-1.51(m,12H), 1.43-1.16(m,3H), 1.13-0.95(m,2H). LC / MS (Method 7): retention time 2.99 min, UV purity (220 nm) 99.4%, m / z observed mass 517.3. SFC (Method 10): Retention time 4.87 minutes, UV purity (220 nm) >97%.
[0084] Example 12: Plasma stability assay Frozen human plasma (stored at -80°C) was thawed in a water bath and subsequently centrifuged at 3200xg for 5 min to remove debris. The pH value of the supernatant was then measured and adjusted to 7.4±0.1 by adding 1% phosphoric acid or 1N sodium hydroxide.
[0085] For each test compound, 2 microL of dosing solution (50 microM for test compound and positive control; 100 microM for propantheline bromide) was spiked into 98 microL of blank plasma to give a final concentration of 1 microM test compound and 2 microM positive control.
[0086] Test compounds and positive controls were incubated in duplicate with human plasma (final DMSO concentration less than 1%) at different time points (0, 0.5, 1, 2, 4, and 6 hours) in a water bath at 37° C. At each corresponding time point, the incubation was stopped by adding an appropriate volume of quenching solution to stop the reaction.
[0087] Plasma samples were then vortexed briefly and then centrifuged at 3200xg for 20 min. Supernatants were transferred to 96-well plates and diluted 1:2 with 200 microL of ultrapure water prior to LC-MS / MS analysis. Analyte / internal standard peak area ratios (PAR) were used to semiquantitatively measure test and control compound concentrations. Percentages of test compound remaining at individual time points relative to the 0 min sample were reported.
[0088] For the determination of the in vitro elimination constants, k, of parent drug and control, the analyte / internal standard peak area ratios were converted to percentage remaining by the following formula:
number
[0089] The percentage of metabolite formation was calculated by the analyte / internal standard peak area ratio relative to the TO (absolute) of the metabolite drug and converted to a percentage.
[0090] The half-lives (T1 / 2) of the parent drug and control compounds were calculated from a log-linear plot of the analyte / internal standard peak area ratio versus time (T1 / 2=0.693 / ke).
[0091] Compounds 1a2, 1b2, 2a2, and 2b2 were incubated in human plasma as described above and half-lives of 0.5-1.5 hours were determined by the formation of 15-35% 4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1,2,2-trimethylpiperazine and 4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d3)piperazine, respectively. The present invention may include the following aspects. [1] 4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1,2,2-trimethylpiperazine in the form 1a or 1b or 4-((1R,3S)-6-chloro-3-(phenyl-d 5 )-2,3-Dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d 3 ) Prodrug of piperazine [ka] (In the formula, X - is an optionally fluorinated anion such as a halide anion, such as chloride, bromide, or iodide, a mesylate, a tosylate, a trifluoromethanesulfonate, or a nonafluorobutanesulfonate, 1 ~C 10 Optionally fluorinated linear or branched C such as sulfonate and trifluoroacetate 1 ~C 11 carboxylate); or a pharma- ceutically acceptable salt thereof. [2] R is a linear or branched chain C 1 ~C 11 Alkyl and C 3 ~C 10 2. The prodrug of claim 1, or a pharma- ceutically acceptable salt thereof, wherein the prodrug is selected from the group consisting of cycloalkyl. [3] 3. The prodrug or pharma- ceutically acceptable salt thereof of any one of claims 1 and 2, wherein R is selected from the group consisting of methyl, tertbutyl, n-undecyl, and cyclohexylmethyl. [4] 4. The prodrug of claim 1, wherein the pharma- ceutically acceptable salt is selected from the group consisting of salts formed from hydrochloric acid, hydrobromic acid, phosphoric acid, nitrous acid, sulfuric acid, benzoic acid, citric acid, gluconic acid, lactic acid, maleic acid, succinic acid, tartaric acid, acetic acid, propionic acid, oxalic acid, maleic acid, fumaric acid, glutamic acid, pyroglutamic acid, salicylic acid, salicylic acid, saccharin, and sulfonic acids such as methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, and benzenesulfonic acid. [5] each of which is a halide anion such as chloride, bromide, or iodide; an optionally fluorinated C such as mesylate, tosylate, trifluoromethanesulfonate, or nonafluorobutanesulfonate; 1 ~C 10 Optionally fluorinated linear or branched C such as sulfonate and trifluoroacetate 1 ~C 11 carboxylates, (R)-1-(acetoxymethyl)-4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1,2,2-trimethylpiperazin-1-ium, (S)-1-(acetoxymethyl)-4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1,2,2-trimethylpiperazin-1-ium, (R)-1-(acetoxymethyl)-4-((1R,3S)-6-chloro-3-(phenyl-d 5 )-2,3-Dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d 3 ) piperazine-1-ium, (S)-1-(acetoxymethyl)-4-((1R,3S)-6-chloro-3-(phenyl-d 5 )-2,3-Dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d 3 ) piperazin-1-ium, (R)-4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-methyl-1-((pivaloyloxy)methyl) piperazin-1-ium, (S)-4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-methyl-1-((pivaloyloxy)methyl) piperazin-1-ium, (R)-4-((1R,3S)-6-chloro-3-(phenyl-d 5 )-2,3-Dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d 3 )-1-((pivaloyloxy)methyl)piperazin-1-ium, (S)-4-((1R,3S)-6-chloro-3-(phenyl-d 5 )-2,3-Dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d 3 )-1-((pivaloyloxy)methyl)piperazin-1-ium, (R)-4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1-((dodecanoyloxy)methyl)-1,2,2-trimethylpiperazin-1-ium, (S)-4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1-((dodecanoyloxy)methyl)-1,2,2-trimethylpiperazin-1-ium, (R)-4-((1R,3S)-6-chloro-3-(phenyl-d 5 )-2,3-Dihydro-1H-inden-1-yl)-1-((dodecanoyloxy)methyl)-2,2-dimethyl-1-(methyl-d 3 ) piperazine-1-ium, (S)-4-((1R,3S)-6-chloro-3-(phenyl-d 5 )-2,3-Dihydro-1H-inden-1-yl)-1-((dodecanoyloxy)methyl)-2,2-dimethyl-1-(methyl-d 3 ) piperazin-1-ium, (R)-4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1-((2-cyclohexylacetoxy)methyl)-1,2,2-trimethylpiperazin-1-ium, (S)-4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1-((2-cyclohexylacetoxy)methyl)-1,2,2-trimethylpiperazin-1-ium, (R)-4-((1R,3S)-6-chloro-3-(phenyl-d 5 )-2,3-Dihydro-1H-inden-1-yl)-1-((2-cyclohexylacetoxy)methyl)-2,2-dimethyl-1-(methyl-d 3 ) piperazine-1-ium, (S)-4-((1R,3S)-6-chloro-3-(phenyl-d 5 )-2,3-Dihydro-1H-inden-1-yl)-1-((2-cyclohexylacetoxy)methyl)-2,2-dimethyl-1-(methyl-d 3 5. The prodrug according to claim 1, wherein the prodrug is selected from the group consisting of: piperazine-1-ium; or a pharma- ceutically acceptable salt thereof. [6] 6. A pharmaceutical composition comprising the prodrug according to any one of claims 1 to 5 or a pharma- ceutically acceptable salt thereof and one or more pharma- ceutically acceptable excipients. [7] 7. A compound according to any one of claims 1 to 5 or a pharma- ceutically acceptable salt thereof, or a pharmaceutical composition according to claim 6, for use in therapy. [8] Use of a compound or a salt thereof according to any one of claims 1 to 5, or a pharmaceutical composition according to claim 6, for the manufacture of a medicament for the treatment of a central nervous system (CNS) disease. [9] A compound according to any one of claims 1 to 5 or a pharmaceutical composition according to claim 6 for use in a method for the treatment of a CNS disorder.
[10] A method for the treatment of a CNS disorder, comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to any one of claims 1 to 5 or a pharmaceutical composition according to claim 6.
Claims
1. A prodrug of 4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1,2,2-trimethylpiperazine, which is in the form 1a or 1b, or 4-((1R,3S)-6-chloro-3-(phenyl-d 5 )-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d 3 ) a prodrug of piperazine, the prodrug being in the form 2a or 2b 【Chemistry 17】 (In the formula, X - is a halide anion such as chloride, bromide, or iodide; an optionally fluorinated C anion such as mesylate, tosylate, trifluoromethanesulfonate, or nonafluorobutanesulfonate; 1 ~C 10 Optionally fluorinated linear or branched C such as sulfonate and trifluoroacetate 1 ~C 11 a counterion selected from the group consisting of carboxylate; R is a linear or branched C 1 ~C 11 Alkyl and C 3 ~C 10 cycloalkyl); or a pharma- ceutically acceptable salt thereof.
2. 2. The prodrug of claim 1, or a pharma- ceutically acceptable salt thereof, wherein R is selected from the group consisting of methyl, tert-butyl, n-undecyl, and cyclohexylmethyl.
3. 3. The prodrug or pharma- ceutically acceptable salt thereof of any one of claims 1 and 2, wherein the pharma- ceutically acceptable salt is selected from the group consisting of salts formed from hydrochloric acid, hydrobromic acid, phosphoric acid, nitrous acid, sulfuric acid, benzoic acid, citric acid, gluconic acid, lactic acid, maleic acid, succinic acid, tartaric acid, acetic acid, propionic acid, oxalic acid, maleic acid, fumaric acid, glutamic acid, pyroglutamic acid, salicylic acid, salicylic acid, saccharin, and sulfonic acids, such as methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, and benzenesulfonic acid.
4. each of which is a halide anion such as chloride, bromide, or iodide; an optionally fluorinated C such as mesylate, tosylate, trifluoromethanesulfonate, or nonafluorobutanesulfonate; 1 ~C 10 Optionally fluorinated linear or branched C such as sulfonate and trifluoroacetate 1 ~C 11 in combination with a counterion selected from the group consisting of carboxylates, (R)-1-(acetoxymethyl)-4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1,2,2-trimethylpiperazin-1-ium, (S)-1-(acetoxymethyl)-4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1,2,2-trimethylpiperazin-1-ium, (R)-1-(acetoxymethyl)-4-((1R,3S)-6-chloro-3-(phenyl-d 5 )-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d 3 ) piperazine-1-ium, (S)-1-(acetoxymethyl)-4-((1R,3S)-6-chloro-3-(phenyl-d 5 )-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d 3 ) piperazine-1-ium, (R)-4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-methyl-1-((pivaloyloxy)methyl)piperazin-1-ium, (S)-4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-methyl-1-((pivaloyloxy)methyl)piperazin-1-ium, (R)-4-((1R,3S)-6-chloro-3-(phenyl-d 5 )-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d 3 )-1-((pivaloyloxy)methyl)piperazin-1-ium, (S)-4-((1R,3S)-6-chloro-3-(phenyl-d 5 )-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d 3 )-1-((pivaloyloxy)methyl)piperazin-1-ium, (R)-4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1-((dodecanoyloxy)methyl)-1,2,2-trimethylpiperazin-1-ium, (S)-4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1-((dodecanoyloxy)methyl)-1,2,2-trimethylpiperazin-1-ium, (R)-4-((1R,3S)-6-chloro-3-(phenyl-d 5 )-2,3-dihydro-1H-inden-1-yl)-1-((dodecanoyloxy)methyl)-2,2-dimethyl-1-(methyl-d 3 ) piperazine-1-ium, (S)-4-((1R,3S)-6-chloro-3-(phenyl-d 5 )-2,3-dihydro-1H-inden-1-yl)-1-((dodecanoyloxy)methyl)-2,2-dimethyl-1-(methyl-d 3 ) piperazine-1-ium, (R)-4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1-((2-cyclohexylacetoxy)methyl)-1,2,2-trimethylpiperazin-1-ium, (S)-4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1-((2-cyclohexylacetoxy)methyl)-1,2,2-trimethylpiperazin-1-ium, (R)-4-((1R,3S)-6-chloro-3-(phenyl-d 5 )-2,3-dihydro-1H-inden-1-yl)-1-((2-cyclohexylacetoxy)methyl)-2,2-dimethyl-1-(methyl-d 3 ) piperazine-1-ium, (S)-4-((1R,3S)-6-chloro-3-(phenyl-d 5 )-2,3-dihydro-1H-inden-1-yl)-1-((2-cyclohexylacetoxy)methyl)-2,2-dimethyl-1-(methyl-d 3 ) Piperazine-1-ium The prodrug or a pharma- ceutically acceptable salt thereof according to any one of claims 1 to 3, which is selected from the group consisting of:
5. A pharmaceutical composition comprising the prodrug of any one of claims 1 to 4 or a pharma- ceutically acceptable salt thereof and one or more pharma- ceutically acceptable excipients.
6. A prodrug according to any one of claims 1 to 4 or a pharma- ceutically acceptable salt thereof or a pharmaceutical composition according to claim 5 for use in therapy.
7. Use of the prodrug or a pharma- ceutically acceptable salt thereof according to any one of claims 1 to 4, or the pharmaceutical composition according to claim 5, for the manufacture of a medicament for the treatment of a central nervous system (CNS) disease.
8. A prodrug according to any one of claims 1 to 4 or a pharma- ceutically acceptable salt thereof, or a pharmaceutical composition according to claim 5, for the treatment of a CNS disease.
9. A pharmaceutical composition comprising the prodrug of any one of claims 1 to 4 or a pharma- ceutically acceptable salt thereof for the treatment of a CNS disorder.
Citation Information
Patent Citations
indane derivative
JP1994503073A
1-piperazino-1,2-dihydroindene derivatives
JP1995505895A
trans-1-(6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine
JP2007502784A
Quaternary ammonium salt prodrugs
JP2013516465A
Deuterated 1-piperazino-3-phenylindan for the treatment of schizophrenia
JP2014520140A
